- Featured Product
- KD/KO Validated
STK17B Polyclonal antibody
STK17B Polyclonal Antibody for IHC, WB, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human
Applications
IHC, WB, ELISA
Conjugate
Unconjugated
验证数据展示
经过测试的应用
| Positive WB detected in | A375 cells, HepG2 cells, K-562 cells |
| Positive IHC detected in | human lymphoma tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Planning an IHC experiment? We recommend our IHCeasy STK17B Ready-To-Use IHC Kit. STK17B primary antibody included.
推荐稀释比
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunohistochemistry (IHC) | IHC : 1:100-1:400 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
发表文章中的应用
| KD/KO | See 1 publications below |
| IHC | See 1 publications below |
产品信息
The immunogen of 26600-1-AP is STK17B Fusion Protein expressed in E. coli.
| Tested Applications | IHC, WB, ELISA |
| Cited Applications | IHC |
| Tested Reactivity | human |
| Cited Reactivity | human |
| Immunogen | STK17B fusion protein Ag24389 种属同源性预测 |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Full Name | serine/threonine kinase 17b |
| Synonyms | DRAK2, serine/threonine kinase 17b, STK17B |
| Calculated Molecular Weight | 372 aa, 42 kDa |
| Observed Molecular Weight | 42 kDa |
| GenBank Accession Number | BC016040 |
| Gene Symbol | STK17B |
| Gene ID (NCBI) | 9262 |
| RRID | AB_2880570 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | O94768 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
Serine/threonine kinase 17B (STK17B), also named as DRAK2, whose gene is located on chromosome 2 (2q32.3), was first reported by Sanjo et al. in 1998 (PMID: 9786912). STK17B has been identified as a promising therapeutic target for type 1 diabetes, multiple sclerosis, and graft rejection. There are also some reports demonstrated that STK17B was related to apoptosis in various cell types, such as islet β-cells and acute myeloid leukemia cells. Some researches revealed that STK17B was deregulated in some cancers and have important role in cancer progression (PMID: 29445189). It has an indispensable role in NAFLD/NASH and offer a potential therapeutic arget for this disease (PMID: 34614409).
实验方案
| Product Specific Protocols | |
|---|---|
| WB protocol for STK17B antibody 26600-1-AP | Download protocol |
| IHC protocol for STK17B antibody 26600-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
Cell Metab DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing.
|
